A Danish biotech company, pioneering in the intersection of gene therapy and microbiome medicine, has achieved a valuation close to 200 million USD. The firm focuses on engineering bacterial strains with CRISPR technology to create living therapeutics that can precisely target and correct disease-associated genetic or microbial imbalances. \n\nThe platform utilizes advanced CRISPR delivery tools to modify microbiome-derived species, enabling precise gene editing and enhanced patient outcomes for ailments like metabolic disorders and gastrointestinal infections. Notably, the company's lead candidate, designed to target a specific monogenic mutation-sart type gut disorder, has entered Phase I/IIa clinical. Its early data highlights robust biological activity in terms of persistent ameliorative; enhanced safety proofs alongside critical endpoints are watched especially amidst